Much research into the impact of hematopoietic cell transplantation (HCT) on recipients' symptoms, functioning and health-related quality of life uses diverse patient-reported outcome (PRO) measures. Robust conclusions regarding PROs in HCT patients are constrained by methodological issues, including the use of multiple different and noncomparable assessment measures. We reviewed 114 publications addressing PROs in HCT patients. Although three multi-item measures were most frequently used (FACT-BMT, n = 28; European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30, n = 26; and SF-36, n = 26), 25 additional measures were used in more than one study. Another 50 measures were used in single studies. Over 50% of studies used more than one measure. We recommend that the field agrees upon a set of measures to address the core domains important to patients, to reduce heterogeneity and allow comparisons across studies and between different populations. Measures should be available in a free and easily accessible manner internationally. We discuss the relative benefits of the National Institutes of Health-supported Patient-Reported Outcomes Measurement Information System (PROMIS) system to achieve these goals. To further address these issues, the Blood and Marrow Transplant Clinical Trials Network has recently created a task force to implement PROMIS measures alongside traditional PRO measures in future clinical trials. Robust comparisons between measures in this setting may allow for the development of a standard for HCT patients.
INTRODUCTION
Patient-reported outcomes (PROs) are generally understood to encompass symptoms, functional status and perceptions of health status or health-related quality of life (HRQoL) as reported directly by the patient without interpretation by clinicians (http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDe velopmentToolsQualificationProgram/ucm370262.htm; accessed on 2 July 2015). The importance of the concepts that the PROs measure is endorsed by patients, particularly as therapies improve and long-term survivorship increases. In addition to survival, the American Society of Clinical Oncology recognizes the importance of HRQoL. 1 There is general agreement that using PROs to assess HRQoL is the gold standard: accuracy and completeness are enhanced when patients report on their health status directly, 2 physicians frequently overestimate HRQoL compared with patients' self-reports 3 and parents underestimate the HRQoL of their children. 4, 5 There are collateral benefits too. At least two clinical studies, including a randomized controlled trial, show that the incorporation of PROs into hematopoietic cell transplantation (HCT) follow-up care can result in better patient-physician communication and enhance patient satisfaction. 6, 7 There is a large body of literature addressing the importance of PROs to HCT patients, both in the early posttransplant and in the longer term survivorship periods. However, there is a lack of consensus about the best measures to use. In addition, little is known about how physicians interpret or use PRO results from research studies in assessing their patients and recommending treatments. 8 The aim of this study was to review the literature to summarize the past and current landscape of multi-item PRO measures in the assessment of health status or HRQoL in patients undergoing HCT and to propose strategies to harmonize the measures for PRO data collection in future research studies.
METHODS
A PubMed search was conducted on 21 October 2014 using the following search terms: QoL and Bone Marrow Transplantation (BMT), HRQoL and BMT, QoL and Hematopoietic Stem Cell Transplantation and HRQoL and Hematopoietic Stem cell transplantation. These search terms were chosen to mirror those used by Pidala et al. 9 Criteria for inclusion were: allogeneic transplants alone or allogeneic and autologous transplants, adult recipients and at least one quantitative multi-item PRO measure of health status or HRQoL. Reports of autologous transplantation alone were excluded as in the report of Pidala et al. 9 and in view of the great diversity of indications for which these transplantations were performed. This search yielded 2171 publications. Duplicates (n = 574), papers prior to 2004 (n = 650) and papers not in English (n = 56) were removed. Studies dealing with a pediatric population (n = 59) only or autologous transplantation, including transplantation for a solid tumor or autoimmune indication (n = 816) only, were removed. PROs related to a specific intervention, such as the use of an exercise program (n = 16) were also removed, as they used measures specific to the targeted intervention rather than addressing general outcomes. A total of 59 studies thus fit the criteria for inclusion.
Three large reviews with similar inclusion criteria (but different objectives) have been published [9] [10] [11] and were considered in this review. Fifty-five studies identified in those reviews, but not in the current literature search, were added, resulting in a final number of 114 manuscripts included in this review.
Multi-item PRO measures were identified from the methods sections of the papers or from the relevant tables in the reviews by Pidala et al., 9 Mosher et al. 11 and Braamse et al. 10 In addition, we reviewed the multi-item PRO measures used in Blood and Marrow Transplant Clinical Trials Network (BMT CTN) prospective clinical trials since 2004. The BMT CTN is a National Institutes of Health (NIH)-funded multicenter trials network addressing issues in HCT. The study and manuscript were approved by the BMT CTN publications committee.
RESULTS

Measures
In the 114 studies, there were 28 multi-item PRO measures used in two or more studies involving the HCT population ( Table 1) . The measures most frequently used were the FACT-BMT in 28 studies, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ)-C30 in 26 studies and the SF-36 in 26 studies. Only two other measures were used in 45 studies, the Sickness Impact Profile (SIP) and the Hospital Anxiety and Depression Scale. Of the five most commonly used measures, one is specific for cancer patients (EORTC) and one for BMT (FACT-BMT), whereas the others were all developed in general patients and/or the healthy population. Twenty-five other multi-item PRO measures were each used in 2-4 studies (Table 1) , and 450 additional measures, addressing multiple areas of health, were used in at least one study (Table 2 ). Over 50% of the studies reviewed used more than one measure for the PRO assessment.
Domains/subscales Table 3 shows the domains that are addressed by the most commonly used measures. The measures are extremely diverse in the domains that they capture. As shown, the top three have multiple overlapping domains, although, as discussed below, there can be poor agreement between what appear to be similar domains. The less frequently used measures commonly address a single domain, for example, depression ( Table 2 ).
Respondent burden
Respondent burden is the time, effort and other demands imposed on the respondents by the survey. The majority of multi-item measures can be completed in a 5-10 min period depending on the number of questions and mode and method of administration (Table 1) . Measures investigating a single domain (for example, fatigue) or a short general overview (for example, SF-12) can be as short as 2-3 min to complete. A few would take significantly longer to complete (for example, SIP or CARES at 30-34 min). The time burden clearly reflects the number of items/questions in the measure, ranging from as few as 5 to as many as 139 questions (Table 1) ; however, the total time taken when multiple different measures are used in studies is not always reported. Almost all of the measures use an ordinal scale and are completed by the patient directly without the need for interviews (that is, self-administered on paper or electronically).
Access
We were also interested in assessing the ease of access for investigators making use of these instruments and included the results in Table 1 . Payment is required for a minority of measures (particularly for non-funded studies), however, many of the measures require a license or permission for their use. In some cases, the scores cannot be generated without access to proprietary scoring algorithms.
Blood and marrow transplant clinical trials network
We reviewed the studies performed by the BMT CTN, which had a PRO as a primary (n = 1) or secondary outcome (n = 8) (one pediatric study excluded) in 18 trials performed since 2004. Ten different multi-item measures were used in these studies. As in the observational studies, the most commonly used measures were the SF-36 (n = 6) and FACT-BMT (n = 7), with only one study using a single instrument. In one study, PROs were the primary end point (BMT CTN 0902) and seven separate multi-item measures were used here.
DISCUSSION
Our study shows that many different multi-item measures are used to assess the PROs of patients undergoing HCT. We are not the first investigators to make this observation and call for harmonization of practice. In fact, virtually all recent reviews addressing PROs in HCT point out the limitations in comparing studies due to heterogeneity in the measures used, but to date no collaborative groups have adopted proactive strategies to address this issue in a definitive manner. 2, 7, 10, 12 An additional problem, highlighted by Pidala et al., 9 is that although some of the PRO measures used are specific for the HCT population, many were designed for the general population. This leads to the incorporation of multiple measures within a single study to address both HCT-specific issues and also cover more general concerns. There are potential problems with this approach. In many cases, there is overlap of similar domains among the measures selected resulting in increased burden for the patients completing measures with no clear added benefit and a potential for increased missing/incomplete data. Moreover, assessment of similar domains by different measures may result in conflicting interpretations. 13 For example, Kopp et al. 14 compared results from the FACT-BMT and the EORTC QLQ-C30 in HCT patients and found poor agreement between some theoretically similar domains (for example, emotional). These are two of the most commonly used measures and are very seldom used together in studies, but Kopp's study calls into question the validity of comparisons between studies that use one or the other.
Perhaps, most importantly, the use of the large number of different measures makes it difficult to compare the impact of different transplantation strategies on PROs, even if the time points measured and patient populations are similar. The impact of the transplantation procedure on PROs is also limited by the cross-sectional nature of many studies, with no baseline/ pretransplant assessment for comparison. Therefore, although there is no paucity of validated measures to assess PROs after HCT, there are barriers to using the accumulated data to calculate general transplant 'norms' (to which transplant patients and their physicians can compare themselves).
Transplantation is a relatively rare treatment within any individual country, and international collaboration is a hallmark of the transplantation community. Inclusion of PROs is hampered if multi-item measures are not translated and validated in multiple languages besides English. With increased diversity of language groups within individual countries, this is an issue within borders too, especially for clinical trials or research studies that frequently exclude non-English speaking patients because of lack of validated instruments in all relevant languages.
To begin the process of coming to a consensus on measuring PROs in HCT, it is important to first agree which domains should be included in the assessments for HCT patients. Core domains should include physical, mental and social components, with the consideration of measuring social functioning at baseline, and a limited set of measures to address these domains is essential. This set of measures should be easily accessible and not too burdensome for patients to complete. Once a standard set of measures is agreed upon by the field, more extensive additional measures could be endorsed for certain settings, using measures that complement the core items without duplication. Some areas that researchers 10 have suggested may be important, but which are not included in most multi-domain measures, are sexual function and intimacy, cognitive functioning, social and role functioning (for example, return to work, concern for caregivers, relationship difficulties and post-traumatic growth). An attractive solution may be to build new HCT-specific questionnaires (both 'core' and 'extended') from items within a single system. In most of the reviewed studies, measures were completed by the patients using pen and paper. Electronic methods may have several advantages in the modern era where access to the internet and comfort levels with communicating electronically is widespread. The Pew report in 2014 showed that 87% of American adults now use the internet, with near-saturation usage among those living in households earning $75,000 or more (99%), young adults aged 18-29 (97%) and those with college degrees (97%). Among the White, African-American and Hispanic populations, it is 83%, 77% and 71%, respectively (http://www.pewinternet.org/ 2014/02/27/part-1-how-the-internet-has-woven-itself-into-ameri can-life/). In addition, 470% of internet users access the internet for health information. Although this figure is generally lower in the developing world, internet usage has increased from~20% in 2010 to 32% in 2014 with no sign of a plateau (https://en. wikipedia.org/wiki/Global_Internet_usage). This is an especially attractive option when considering large-scale collection of PRO, such as may occur in multicenter clinical trials or registry-based studies, and avoids additional data entry. A critical advantage would be the possibility of linking the PRO directly to the Electronic Health Record (EHR), functionality that is rarely available currently, but is anticipated to be more widespread in the future. This could advance efforts to improve routine patient care in a Abbreviations: F = free; GvHD = graft versus host disease; HCT = hematopoietic cell transplantation; L = requires license; LD = limited domain; M = multidimensional; n = no; NA = not applicable; P = payment required; R = register; y = yes.
non-research setting through 'comprehensive' patient health information with incorporation of health behaviors and psychosocial issues into the medical record. 15 It will be important to test the same measures used in research in this setting, understanding that real-time reporting, interpretation and the potential use of 'triggers' for clinical intervention is an added requirement. These issues may be less specific to the measures used than to the technology through which they are employed. In addition, appropriate consenting of patients through the EHR, with availability of these data to centralized research organizations, will allow for the same tools to be informative both for immediate clinical care as well as research analyses. The feasibility of frequent electronic PRO collection, with 'real-time' physician review, has been demonstrated in several settings, 7, 16, 17 including HCT. 18, 19 The BMT CTN attempted to address the issue of harmonization of measures in HCT with the development of a white paper in 2012 advocating for the use of similar instruments and assessment points in all studies (https://web.emmes.com/study/bmt2/public/ SOSS/BMT%20CTN%20SOSS%20QOL%20white%20paper%20QOL. pdf). The white Paper acknowledges that although most studies will use a similar backbone of FACT-BMT and SF-36, it is often necessary to add additional measures in individual studies to adequately capture all aspects of PROs of interest to the study investigators and of relevance to the intervention being tested. The white paper also recommends that, in general, free or academically discounted instruments should be favored. More recently, this group made a specific recommendation for the inclusion of the NIH patients repeated outcomes measurement information systems (PROMIS) measures into BMT CTN studies. Development of a task force to implement this recommendation is underway.
PROMIS captures patient-reported health status using a set of highly reliable, valid, flexible, precise and responsive assessment tools. 20 PROMIS consists of item banks with a variable number of questions that can be combined to form multi-item measures of varying length and complexity. Because each item is mapped onto a common metric, measures of differing length can be compared with each other. 13 Fixed-length multidimensional measures are available, including profiles with 29, 43 or 57 questions. There is also a Global Health Questionnaire of just 10 questions. Forms and item banks are available for adults, children and parent-proxy reporting. A more recent benefit is the incorporation of PROMIS into Epic, an EHR widely available in US, allowing patients to access and complete the measures directly through MyChart (Epic Systems Corporation, Verona, WI, USA), with the results being made available to their health-care providers. 21 This functionality is not currently operational at all Epic-using centers. Addressing another area of need, PROMIS has an international working group translating the measures into multiple languages, several of which are already completed, including Spanish.
A current disadvantage to this system is that it does not contain many items that are more specifically HCT-related, for example, those associated with graft versus host disease (GvHD), ongoing immunosuppression, recurrent infections and specific late effects such as treatment-related malignancies. In addition, few studies in HCT to date have utilized PROMIS measures. If PROMIS is to meet the needs of the HCT community, these issues must be addressed.
RECOMMENDATIONS
Use the same core measures in all research studies of HCT patients The benefit of this approach is obvious as it promotes aggregation of data and comparison among studies. It also allows investigators to explore better any differences or similarities among different study populations. It could potentially allow development of a transplant patient 'norm' to which patients could be compared. Ideally, a single tool taking o10 min to complete and translated into several languages would be beneficial. Use a system which is free and easy to access To achieve international compliance with a single system of PRO tools in HCT, these should be free and easily accessible, including on mobile devices. A system which interacts directly with the electronic medical record is very desirable.
Ensure a low burden for the patient Ideally a brief measure that does not sacrifice precision, but covers many common domains could be included for all patients.
Use a single system of items which is versatile Where a common brief measure is insufficient to study all aspects of interest, additional pre-existing validated items could be added. This would remove the issue of overlap when multiple measures from different systems are used and may allow a multi-item measure, tailored to the HCT population, to be developed.
CONCLUSION
Developing a HRQoL focused task force within the BMT CTN provides an opportunity for the consistent implementation of the above recommendations in the majority of HCT patients entering a clinical trial in US. In the short term, the use of PROMIS measures in BMT CTN studies alongside instruments with a longer track record (specifically, the SF-36 and FACT-BMT) would serve to validate the measures in this population, although taking advantage of the ongoing NIH-supported efforts of electronic data capture and translation, using a system that is freely available. Post hoc comparative analyses between these measures within individual studies as well as in a cross-sectional manner across studies may result in robust conclusions, which we hope will promote adoption of the most discriminating common measures by the community in general. Decisions on which measures to use in studies addressing specific areas/domains of PROs (for example, GvHD) should be based on the goal of preserving the ability of each study to meet its PRO-specific aims while ensuring the comparability and usefulness of PRO data collection beyond the needs of a single study. Abbreviation: BMT = bone marrow transplantation; GvHD = graft versus host disease.
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